Clinical Trial Update: 177Lu-PSMA (177Lu-PNT2002) in PSMA-Positive Adenoid Cystic Carcinoma [Phase 2]

View source ↗

Summary

A Phase 2 trial of 177Lu-PNT2002 (177Lu-PSMA radiopharmaceutical) for PSMA-positive Adenoid Cystic Carcinoma was terminated. The update does not include trial r…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Adenoid Cystic Carcinoma

Drugs mentioned

• 177Lu-PNT2002 (177Lu-PSMA radiopharmaceutical) (Lutetium-177 labeled PSMA-targeted radiopharmaceutical)

Snippet

Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Conditions: Adenoid Cystic Carcinoma | Phase 2 | Status: TERMINATED